Ultragenyx Pharma Posts Wider Loss In Q3 - Quick Facts

(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) reported a third-quarter net loss of $79.2 million, or $1.87 per share, compared to a net loss of $64.9 million, or $1.64 per share, prior year. On average, 16 analysts polled by Thomson Reuters expected the company to report a loss per share of $1.86 for the quarter. Analysts' estimates typically exclude special items.

"Burosumab and vestronidase alfa regulatory submissions have been accepted and regulatory review is progressing well in both the US and European Union. We are preparing for a near-term potential launch of vestronidase alfa with a PDUFA date of November 16," said Emil Kakkis, CEO of Ultragenyx.